Overlooking Evolution: A Systematic Analysis of Cancer Relapse and Therapeutic Resistance Research

被引：72

作者：

Aktipis, C. Athena ^{[1
,2
]}

Kwan, Virginia S. Y. ^{[1
]}

Johnson, Kathryn A. ^{[1
]}

Neuberg, Steven L. ^{[1
]}

Maley, Carlo C. ^{[2
]}

机构：

[1] Arizona State Univ, Dept Psychol, Tempe, AZ 85287 USA

[2] Univ Calif San Francisco, Ctr Evolut & Canc, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA

来源：

PLOS ONE | 2011年 / 6卷 / 11期

基金：

美国国家卫生研究院;

关键词：

GENE AMPLIFICATION; IMATINIB RESISTANCE; ACQUIRED-RESISTANCE; BARRETTS-ESOPHAGUS; IN-SITU; CELL; PROGRESSION; MUTATIONS; HETEROGENEITY; CHEMOTHERAPY;

D O I：

10.1371/journal.pone.0026100

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Cancer therapy selects for cancer cells resistant to treatment, a process that is fundamentally evolutionary. To what extent, however, is the evolutionary perspective employed in research on therapeutic resistance and relapse? We analyzed 6,228 papers on therapeutic resistance and/or relapse in cancers and found that the use of evolution terms in abstracts has remained at about 1% since the 1980s. However, detailed coding of 22 recent papers revealed a higher proportion of papers using evolutionary methods or evolutionary theory, although this number is still less than 10%. Despite the fact that relapse and therapeutic resistance is essentially an evolutionary process, it appears that this framework has not permeated research. This represents an unrealized opportunity for advances in research on therapeutic resistance.

引用

页数：9

共 70 条

[1] Simple and effective confidence intervals for proportions and differences of proportions result from adding two successes and two failures
Agresti, A
Caffo, B
[J]. AMERICAN STATISTICIAN, 2000, 54 (04) : 280 - 288
[2] Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents
Agulnik, Mark
Oza, Amit M.
Pond, Gregory R.
Siu, Lillian L.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (30) : 4801 - 4807
[3] AKTIPIS CA, 2010, EVOL MED REV
[4] Evolution by any other name: Antibiotic resistance and avoidance of the E-word
Antonovics, Janis
Abbate, Jessica L.
Baker, Christi Howell
Daley, Douglas
Hood, Michael E.
Jenkins, Christina E.
Johnson, Louise J.
Murray, James J.
Panjeti, Vijay
Rudolf, Volker H. W.
Sloan, Dan
Vondrasek, Joanna
[J]. PLOS BIOLOGY, 2007, 5 (02) : 137 - 140
[5] High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance
Branford, S
Rudzki, Z
Walsh, S
Grigg, A
Arthur, C
Taylor, K
Herrmann, R
Lynch, KP
Hughes, TP
[J]. BLOOD, 2002, 99 (09) : 3472 - 3475
[6] Pattern of relapse in surgical treated patients with thoracic esophageal squamous cell carcinoma and its possible impact on target delineation for postoperative radiotherapy
Cai, Wen-Jie
Xin, Pei-Ling
[J]. RADIOTHERAPY AND ONCOLOGY, 2010, 96 (01) : 104 - 107
[7] Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing
Campbell, Peter J.
Pleasance, Erin D.
Stephens, Philip J.
Dicks, Ed
Rance, Richard
Goodhead, Ian
Follows, George A.
Green, Anthony R.
Futreal, P. Andy
Stratton, Michael R.
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (35) : 13081 - 13086
[8] RESISTANCE TO METHOTREXATE DUE TO GENE AMPLIFICATION IN A PATIENT WITH ACUTE-LEUKEMIA
CARMAN, MD
SCHORNAGEL, JH
RIVEST, RS
SRIMATKANDADA, S
PORTLOCK, CS
DUFFY, T
BERTINO, JR
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1984, 2 (01) : 16 - 20
[9] Evolutionary origins of human apoptosis and genome-stability gene networks
Castro, Mauro A. A.
Dalmolin, Rodrigo J. S.
Moreira, Jose C. F.
Mombach, Jose C. M.
de Almeida, Rita M. C.
[J]. NUCLEIC ACIDS RESEARCH, 2008, 36 (19) : 6269 - 6283
[10] Timeline - Chemotherapy and the war on cancer
Chabner, BA
Roberts, TG
[J]. NATURE REVIEWS CANCER, 2005, 5 (01) : 65 - 72

← 1 2 3 4 5 6 7 →